Trial reportJournal of veterinary pharmacology and therapeutics2016
Effects of oral cyclosporine on canine T-cell expression of IL-2 and IFN-gamma across a 12-h dosing interval.
Trial report in Journal of veterinary pharmacology and therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.Scientific reports · 2026Trial
- Treatment-Associated Differences in Serum Cytokine Profiles in Canine Atopic Dermatitis: A Cross-Sectional Study.Animals : an open access journal from MDPI · 2026Article
- Serum Cytokine Profiles and Their Association with Clinical Severity in Dogs with Atopic Dermatitis.Animals : an open access journal from MDPI · 2026Article
- Ex vivo effects of oclacitinib and cyclosporin A on canine immune response to Leishmania infantum.Scientific reports · 2026Article
- Of potential new treatment targets and polythetic approach in meningoencephalitis of unknown origin: a review.Frontiers in veterinary science · 2024Review
- Porcine-human glioma xenograft model. Immunosuppression and model reproducibility.Cancer treatment and research communications · 2024Article
- Perspectives on pharmacologic strategies in the management of meningoencephalomyelitis of unknown origin in dogs.Frontiers in veterinary science · 2023Review
- Recovery of T-cell function in healthy dogs following cessation of oral cyclosporine administration.Veterinary medicine and science · 2020Article
- Ehrlichia canis in dogs experimentally infected, treated, and then immune suppressed during the acute or subclinical phases.Journal of veterinary internal medicine · 2020Article
- Effects of oral administration of 5 immunosuppressive agents on activated T-cell cytokine expression in healthy dogs.Journal of veterinary internal medicine · 2020Article
- Retrospective evaluation of cyclosporine in the treatment of presumed idiopathic chronic hepatitis in dogs.Journal of veterinary internal medicine · 2019Article
- Toxoplasmosis as a cause of life-threatening respiratory distress in a dog receiving immunosuppressive therapy.Clinical case reports · 2019Article
- Effect of immunosuppressive drugs on cytokine production in canine whole blood stimulated with lipopolysaccharide or a combination of ionomycin and phorbol 12-myristate 13-acetate.Veterinary medicine and science · 2019Article
- Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.The Journal of steroid biochemistry and molecular biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The duration of immunosuppressive effects following oral cyclosporine in dogs is unknown. This study used flow cytometry and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to evaluate the effects of high-dose oral cyclosporine across a 12-h dosing interval. Expression of interleukin-2 (IL-2) and interferon-gamma (IFN-γ) was compared before and after 8 days of cyclosporine at 10 mg/kg every 12 h in six healthy dogs. Samples were collected at 0, 2, 4, and 8 h postdosing for analysis of unactivated and activated T-cell and whole blood cytokine expression using flow cytometry and qRT-PCR, respectively, and at 0, 2, 4, 6, 8, and 10 h postdosing for measurement of cyclosporine concentrations. Flow cytometry and qRT-PCR both demonstrated significant marked reductions in IL-2 and IFN-γ levels at 0, 2, 4, and 8 h after dosing compared to pretreatment levels (P < 0.05) for activated samples, with less consistent effects observed for unactivated samples. Both flow cytometry and qRT-PCR are viable techniques for measuring cyclosporine pharmacodynamics in dogs, yielding comparable results with activated samples. Two hours postdrug administration is the preferred time for concurrent assessment of peak drug concentration and cytokine expression, and T-cell activation is needed for optimal results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.